The Best Biotech CEO of 2013 is...

The Best Biotech CEO of 2013 is Bob Hugin of Celgene (CELG).

In an incredibly strong year for all the big-cap biotech stocks, Hugin steered Celgene to the top of the heap. The multiple myeloma drug Revlimid remains Celgene's most important profit driver, but the company did well to diversify in 2013. Pomalyst, Abraxane and apremilast were all big winners for the company this year. Under Hugin's direction, Celgene also signed a large number of drug development partnerships for early-stage compounds which makes the company a player in emerging technologies.

Congratulations, Bob, for a fantastic year and well-deserved recognition as the Best Biotech CEO of 2013.

Hugin won with 41% of 1,078 votes cast. For his victory, Hugin takes home the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO.

The runner-up this year was John Higgins of Ligand Pharmaceuticals  (LGND) with 25% of votes cast.

Francois Nader of NPS Pharmaceuticals  (NPSP) finished in third place with 11% of the vote, followed closely by Lamberto Andreotti of Bristol-Myers Squibb  (BMY) and Onyx Pharmaceuticals' (now a part of Amgen (AMGN)) Tony Coles.

Congratulation to all of this year's Best Biotech CEO nominees, and thanks to everyone who participated in the voting process.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Three Stocks That Have My Attention

Three Stocks That Have My Attention

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices